L. Pearce

The global landscape of cancer cell therapy

Vanessa M. Hubbard-Lucey, J. O’Donnell-Tormey, Jun Tang, 2018, Nature Reviews Drug Discovery.

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

A. Baruchel, Abraham I. Bassan, G. Vassal, 2021, European journal of cancer.

Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: Results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS).

M. Minden, Z. Estrov, G. Garcia-Manero, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study

E. Eisenhauer, J. Knox, E. Winquist, 2006, Investigational New Drugs.

Trends in the global immuno-oncology landscape

Vanessa M. Hubbard-Lucey, J. O’Donnell-Tormey, Jun Tang, 2018, Nature Reviews Drug Discovery.

Trends in the global immuno-oncology landscape

Laura Pearce, Vanessa M. Hubbard-Lucey, J. O’Donnell-Tormey, 2018, Nature Reviews Drug Discovery.

IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).

J. Blay, G. Demetri, Melissa L. Johnson, 2021 .

Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.

K. Gelmon, J. Dancey, L. Seymour, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.